KINDRED
Kinetoplastid Drug Development: strengthening the preclinical pipeline
| Coordinatore | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Organization address
address: NORTH STREET 66 COLLEGE GATE contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 7˙915˙469 € |
| EC contributo | 5˙999˙991 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2016-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Organization address
address: NORTH STREET 66 COLLEGE GATE contact info |
UK (ST ANDREWS FIFE) | coordinator | 598˙489.44 |
| 2 |
NovAliX
Organization address
address: BOULEVARD SEBASTIEN BRANT BIOPARC contact info |
FR (ILLKIRCH GRAFFENSTADEN) | participant | 992˙400.00 |
| 3 |
IP RESEARCH CONSULTING SASU
Organization address
address: QUAI DES DEUX PONTS 31 contact info |
FR (NOISY LE GRAND) | participant | 653˙718.50 |
| 4 |
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR - IBMC
Organization address
address: RUA DO CAMPO ALEGRE 823 contact info |
PT (PORTO) | participant | 539˙999.20 |
| 5 |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Organization address
address: "FRANKLIN STREET 1111, 12 FLOOR" contact info |
US (OAKLAND CA) | participant | 491˙800.00 |
| 6 |
Innovative Technologies in Biological Systems
Organization address
city: Derio contact info |
ES (Derio) | participant | 413˙064.00 |
| 7 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 365˙400.00 |
| 8 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 359˙609.25 |
| 9 |
SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT
Organization address
address: SOCINSTRASSE 57 contact info |
CH (Basel) | participant | 347˙712.00 |
| 10 |
PHYLOGENE
Organization address
address: 62RTE Nationale 113 contact info |
FR (Bernis) | participant | 313˙590.00 |
| 11 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 308˙750.00 |
| 12 |
FUNDACAO OSWALDO CRUZ
Organization address
address: AVENIDA BRASIL 4365 contact info |
BR (RIO DE JANEIRO) | participant | 247˙204.80 |
| 13 |
THE ALL-INDIA INSTITUTE OF MEDICAL SCIENCES
Organization address
address: ANSARI NAGAR contact info |
IN (NEW DELHI) | participant | 244˙054.00 |
| 14 |
GRAFFINITY PHARMACEUTICALS GMBH
Organization address
address: IM NEUENHEIMER FELD 518 contact info |
DE (HEIDELBERG) | participant | 124˙200.06 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The trypanosomatid diseases, leishmaniasis, Human African trypanosomiasis (HAT) and Chagas disease (CD), continue to impart a heavy toll on human health. The treatments available are limited and threatened by drug resistance with few newdrugs in the pipeline. The KINDReD consortium integrates five leading academic laboratories in Europe (Portugal, United Kingdom, and Switzerland), the USA (California) and South America (Brazil) with high throughput screening (HTS) facilities equally distributed between all three major kinetoplastid parasites. Intracellular amastigote screening will be employed as the most relevant for Leishmania spp and T cruzi. Compound libraries (focused, diversity oriented or natural) will be screened in these systems, as well as compound series devised through target screening and in silico approaches. For carefully chosen protein targets, all three kinetoplastid parasite homologs will be screened against the closest human homolog to establish selectivity. Promising lead compounds will be optimised for efficacy and tolerability in cell-based and animal disease models. Toxicological markers will be evaluated in human cell lines prior to toxicity (acute,subacute,chronic) testing in lower then higher mammals. In parallel, and in line with the FDA's ‘Critical Path Initiative’, several check point controls will be built into the pipeline to flag, identify and allow early correction of potential toxicity/efficacy issues. These will include (i) a systems biology approach to identify drug target and off-target interactions via activity-based chemoproteomics (ii) ‘uptake and metabolism’as potential modulators of drug efficacy and/or resistance and (iii) the establishment of a firm set of rules for drug efficacy and safety in kinetoplastid chemotherapy. Our goal is to strengthen the drug development pipeline in order to achieve at least one new Phase I clinical candidate for each trypanosomatid disease at or shortly after the project completion date.'